We have located links that may give you full text access.
Synthesis and Biological Evaluation of [ 18 F]FECNT-d 4 as a Novel PET Agent for Dopamine Transporter Imaging.
Molecular Imaging and Biology : MIB : the Official Publication of the Academy of Molecular Imaging 2021 April 14
PURPOSE: The dopamine transporter (DAT) is a marker of the occurrence and development of Parkinson's disease (PD) and other diseases with nigrostriatal degeneration. 2β-Carbomethoxy-3β-(4-chlorophenyl)-8-(2-[18 F]-fluoroethyl)nortropane ([18 F]FECNT), an 18 F-labelled tropane derivative, was reported to be a useful positron-emitting probe for DAT. However, the rapid formation of brain-penetrating radioactive metabolites is an impediment to the proper quantitation of DAT in PET studies with [18 F]FECNT. Deuterium-substituted analogues have presented better in vivo stability to reduce metabolites. This study aimed to synthesize a deuterium-substituted DAT radiotracer, [18 F]FECNT-d4 , and to make a preliminary investigation of its properties as a DAT tracer in vivo.
PROCEDURES: The ligand [18 F]FECNT-d4 was obtained by one-step radiolabelling reaction. The lipophilicity was measured by the shake-flask method. Binding properties of [18 F]FECNT-d4 were estimated by in vitro binding assay, biodistribution, and microPET imaging in rats. In vivo stability of [18 F]FECNT-d4 was estimated by radio-HPLC.
RESULTS: [18 F]FECNT-d4 was synthesized at an average activity yield of 46 ± 17 % (n = 15) and the molar activity was 67 ± 12 GBq/μmol. The deuterated tracer showed suitable lipophilicity and the ability to penetrate the blood-brain barrier (brain uptake of 1.72 % ID at 5 min). [18 F]FECNT-d4 displayed a high binding affinity for DAT comparable to that of [18 F]FECNT in rat striatum homogenates. Biodistribution results in normal rats showed that [18 F]FECNT-d4 exhibited a higher ratio of the target to non-target (striatum/cerebellum) at 15 min post administration (5.00 ± 0.44 vs 3.84 ± 0.24 for [18 F]FECNT-d4 vs [18 F]FECNT). MicroPET imaging studies of [18 F]FECNT-d4 in normal rats showed that the ligand selectively localized to DAT-rich striatal regions and the accumulation could be blocked with DAT inhibitor. Furthermore, in the unilateral PD model rat, a significant reduction of the signal was found in the lesioned side relative to the unlesioned side. Striatal standardized uptake value of [18 F]FECNT-d4 remained ~4.02 in the striatum between 5 and 20 min, whereas that of [18 F]FECNT fell rapidly from 4.11 to 2.95. Radio-HPLC analysis of the plasma demonstrated better in vivo stability of [18 F]FECNT-d4 than [18 F]FECNT.
CONCLUSION: The deuterated compound [18 F]FECNT-d4 may serve as a promising PET imaging agent to assess DAT-related disorders.
PROCEDURES: The ligand [18 F]FECNT-d4 was obtained by one-step radiolabelling reaction. The lipophilicity was measured by the shake-flask method. Binding properties of [18 F]FECNT-d4 were estimated by in vitro binding assay, biodistribution, and microPET imaging in rats. In vivo stability of [18 F]FECNT-d4 was estimated by radio-HPLC.
RESULTS: [18 F]FECNT-d4 was synthesized at an average activity yield of 46 ± 17 % (n = 15) and the molar activity was 67 ± 12 GBq/μmol. The deuterated tracer showed suitable lipophilicity and the ability to penetrate the blood-brain barrier (brain uptake of 1.72 % ID at 5 min). [18 F]FECNT-d4 displayed a high binding affinity for DAT comparable to that of [18 F]FECNT in rat striatum homogenates. Biodistribution results in normal rats showed that [18 F]FECNT-d4 exhibited a higher ratio of the target to non-target (striatum/cerebellum) at 15 min post administration (5.00 ± 0.44 vs 3.84 ± 0.24 for [18 F]FECNT-d4 vs [18 F]FECNT). MicroPET imaging studies of [18 F]FECNT-d4 in normal rats showed that the ligand selectively localized to DAT-rich striatal regions and the accumulation could be blocked with DAT inhibitor. Furthermore, in the unilateral PD model rat, a significant reduction of the signal was found in the lesioned side relative to the unlesioned side. Striatal standardized uptake value of [18 F]FECNT-d4 remained ~4.02 in the striatum between 5 and 20 min, whereas that of [18 F]FECNT fell rapidly from 4.11 to 2.95. Radio-HPLC analysis of the plasma demonstrated better in vivo stability of [18 F]FECNT-d4 than [18 F]FECNT.
CONCLUSION: The deuterated compound [18 F]FECNT-d4 may serve as a promising PET imaging agent to assess DAT-related disorders.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app